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cians were asked if they considered that the patient had CGD
and also objective criteria (serum creatinine  2 mg/dl or
MDRD  50 ml/min), were applied. RESULTS: A total of 872
patients were analyzed 62% male, mean (SD) age 54 (13) years.
Ethiology of end stage renal failure: 32.7% chronic glomerulo-
nephritis, 19.8% unknown, 12.4% polycystic disease, 7.6%
chronic pielonephritis, 8% diabetes, 5.9% hypertension, 15.7%
other. Mean (SD) transplant evolution 8.2 (5.1) years. Mean
donor age 42 years. CGD was diagnosed in 35% of the patients
according to the investigators’ criteria and in 55.5% according to
objective criteria. In 40% of the patients that were diagnosed of
CGD by objective criteria the clinician had not considered this
diagnosis. Graft biopsy was performed in 31% of patients with
investigators’ criteria of CGD. The presence of proteinuria con-
ducted to a biopsy more than a rise in serum creatinine. Time
from transplant to biopsy was greater in patients with antipro-
teinuric treatment (p = 0,032). Immunosuppressive treatment
changes were not associated to biopsy histological data. The
creatinine slope showed a direct relationship with the total
number of treated acute rejections (Pearson’s r: 0,12; p < 0.001).
CONCLUSIONS: This study shows an existing difference
between the clinician’s perception of CGD and its objective pres-
ence. Nephrologists are more sensitive to glomerular disease than
to renal impairment itself. Changes in the immunosuppressive
treatment due to presence of CGD are performed late and with
poor results.
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OBJECTIVES: The number of prevalent patients with end-stage
renal disease (ESRD) in Greece has grown nearly 13% since
2003. Approximately 83% of prevalent ESRD patients are on
dialysis, the rest have a functioning kidney transplant. For
ESRD patients needing dialysis, two treatment options are
available, hemodialysis (HD) and peritoneal dialysis (PD). Both
have been shown to have similar outcomes yet most (91%)
dialysis patients in Greece receive HD. The objective of this
evaluation is to project a ﬁve-year impact on total direct dialy-
sis costs if utilization of the less expensive equally, effective PD
were increased to 15% of all dialysis. METHODS: An Excel-
based budget impact model was used to estimate the impact of
a shift in modality utilization. The model takes into account
dialysis modality shares, annual average cost of treating
patients per modality, annual ESRD growth rate, patient years
at risk and years to reach new dialysis modality distribution.
Cost data from a recent Greek study were used. At baseline
(2007) there were 8189 patients undergoing dialysis therapy,
91% using HD and 9% using PD. Annual direct cost per
patient were €36,247 for in-center HD and €30,719 for PD. We
applied a 2% annual ESRD growth rate; set the target PD
modality share at 15%, and that this target would be achieved
in the ﬁfth year. Total costs included equipment/infrastructure,
diagnostic services, drugs and consumables, staff salaries, and
operational costs/overheads. RESULTS: If PD utilization gradu-
ally increases to 15% by 2012, the cumulative 5-year cost
would be reduced by €6.5 million. Alternatively, the savings
could provide an additional 258 patient-years of dialysis treat-
ment. CONCLUSIONS: In Greece, an increased use of PD can
reduce the direct costs of dialysis treatment which then
provides an opportunity to use scarce health care resources on
other pressing needs.
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OBJECTIVES: The number of prevalent patients with end-stage
renal disease (ESRD) in Turkey has grown nearly 36% from
2001 to 2005. Approximately 90% of prevalent ESRD patients
are on dialysis, the rest have a functioning kidney transplant. For
ESRD patients needing dialysis, two treatment options are avail-
able, hemodialysis (HD) and peritoneal dialysis (PD). Both have
been shown to have similar outcomes yet most (87%) dialysis
patients in Turkey receive HD. The objective of this evaluation
is to project a ﬁve-year impact on total direct dialysis costs if
utilization of the less expensive equally effective PD were
increased to 20% of all dialysis. METHODS: An Excel-based
budget impact model was used to estimate the impact of a shift
in modality utilization. The model takes into account dialysis
modality shares, annual average cost of treating patients per
modality, annual ESRD growth rate, patient years at risk and
years to reach new dialysis modality distribution. Cost data from
a recent Turkish study were used. At baseline (2005) there were
39,161 patients undergoing dialysis therapy, 13% using PD.
Annual costs per patient were US$23,342 for in-center HD and
US$17,779 for PD. We applied a 6% annual ESRD growth rate;
set the target PD modality share at 20%, and that this target
would be achieved in the ﬁfth year. Total costs included the costs
of dialysis related supplies (e.g., dialysis solutions) and the cost of
drugs (e.g., erythropoietin). RESULTS: If PD utilization gradu-
ally increases to 20% by 2010, the cumulative 5-year cost would
be reduced by $38.8 million. Alternatively, the savings could
provide an additional 2420 patient-years of dialysis treatment.
CONCLUSIONS: In Turkey, an increased use of PD can reduce
the dialysis and drug-related costs of dialysis treatment which
then provides an opportunity to use scarce health care resources
on other pressing needs.
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OBJECTIVES: To investigate the pharmacoeconomic perfor-
mance of the treatment with solifenacin, a bladder-selective
muscarinic receptor antagonist, as compared to tolterodine and
placebo, in Italian patients with overactive bladder (OAB).
METHODS: A simple Markov model simulates 52-weeks clini-
cal and economical outcomes associated with the treatment with
solifenacin (5 mg/die), tolterodine ER (4 mg/die), and no treat-
ment, in a cohort representative of the Italian OAB population,
relying on RCT efﬁcacy and national cost data, and using 1-week
cycles. Only direct health care costs were considered. The main
analysis is conducted from the point of view of the patient, as
drugs for OAB are not currently reimbursed in Italy, whereas
incontinence medical devices are only to few selected patients. A
complementary scenario was elaborated to explore the conse-
quences of a hypothetical reimbursement decision by the Italian
NHS at half of the current retail price and only to incontinent
and responding OAB patients. RESULTS: Both active treatments
produce signiﬁcant improvements in symptoms and quality of
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life, with an increase in costs of about €540–640 and €680–
780/patient/year with solifenacin and tolterodine, respectively.
Cost-utility analysis indicates that solifenacin dominates toltero-
dine and has an ICUR in the range €7,600—18,600/QALY com-
pared to no treatment. In the subgroup of patients incontinent
at baseline and who respond to the therapy, the increase in costs
with solifenacin results in €100–400/patient/year. The expected
incremental expenditure of the theoretical reimbursement deci-
sion is about €23 millions/year, with an ICUR of about €600–
2,400/QALY. CONCLUSIONS: Solifenacin has the potential to
improve current clinical outcomes of many Italian OAB
patients, at a mean net cost of €540–640/year. The ICUR of the
hypothesized reimbursement decision can expected to be very
favourable.
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OBJECTIVES: Recent clinical data show that a supplemented
very low protein diet (sVLPD) allows to postpone dialysis (HD/
PD) of about one year without increasing risk of death or hospi-
talization in CKD5 elderly patients; here we compared beneﬁts
and costs of sVLPD vs dialysis in these patients. METHODS: A
cost-beneﬁt analysis technique was applied. Direct medical and
non-medical beneﬁts and costs were analysed, from the perspec-
tive of the Italian National Health Service (NHS). We quantiﬁed
resource adsorption for dialysis, keto-amino acid supplements,
hospitalizations, pharmacological therapy, blood and instrumen-
tal tests, medical visits, reimbursement for transportation of
patients in HD and for home treatment of patients in PD. Prices
and tariffs applied in 2007 were used. Results are expressed as
mean € per patient-year. RESULTS: Data from a subgroup of
patients with GFR of 5–7 ml/min/1.73 m2 BSA, participating in a
RCT were analysed. Thirty patients were randomized to dialysis
(age = 77.2 4.6 years; 23 HD, 7 PD); 27 to sVLPD (age = 78.6 6.5
years): during the follow up 19 switched to HD and 2 to PD.
Follow-up was, in mean, 3.24 years in dialysis, and 3.27 years in
sVLPD group, including both diet and following period on dialy-
sis. Erythropoietin (EPO) dose was on average 7,160 IU/patient-
week in sVLPD patients, and 8,104 IU/patient-week in dialysis
patients. Patients cost €45,209/patient-year on dialysis; €10,786/
patient-year during sVLPD and €40,900/patient-year when
shifted to dialysis. Dialysis was the cost driver (€26,000/patient-
year, 60% of costs), main beneﬁt to NHS derived from saving
this costs in the ﬁrst year (mean period in sVLPD) of treatment.
CONCLUSIONS: to our knowledge this is the ﬁrst study analys-
ing beneﬁts and costs of initiating sVLPD whereas dialysis in
CKD5 patients. sVLPD allows to save 1 year per patient of dialysis
and to gain €34,000/patient-year on the NHS’s perspective.
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OBJECTIVES: Overactive bladder is a dysfunction of the lower
urinary tract which causes signiﬁcant impairment to patients’
quality of life and affects a relatively large portion of the popu-
lation. Patients who have failed all conservative treatment
options are faced with managing their incontinence symptoms
through the daily use of incontinence pads, or their retention by
frequent clean intermittent self catheterization. Patients with
severe symptoms may be offered a highly invasive surgical pro-
cedure, such as myectomy, urinary diversion or bladder augmen-
tation but these are all associated with serious complications and
morbidity. The objective is to assess cost-effectiveness of sacral
neuromodulation as a second line treatment option for patients
with OAB in the Dutch setting. METHODS: An economic model
comparing sacral neuromodulation with optimal medical treat-
ment was developed. Health states were deﬁned in terms of ‘cure’
deﬁned as no incontinence or a clinical improvement > 90%,
or ‘improvement’ deﬁned as 50% or greater reduction in main
continence or urgency frequency symptoms. Associated clinical
effectiveness and utility values were taken from published inter-
national clinical studies, and treatment costs were based on
national sources. Analyses from the health care payer’s perspec-
tive were performed for a 10 year time-horizon. RESULTS: The
results of the deterministic cost-effectiveness analysis showed
that sacral neuromodulation provides an additional 1.53 QALY’s
against extra cost of €8222 per patient over a 10 year period.
The corresponding cost-effectiveness ratio was €5732 per QALY
gained. Probabilistic sensitivity analysis showed the robustness of
these results. CONCLUSIONS: Use of sacral neuromodulation
as a treatment option for patients with OAB in The Netherlands
will improve patients’ outcomes at a reasonable cost.
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OBJECTIVES: Performing a 10-year horizon (2007/2016) cost-
effectiveness analysis of the integrated Spanish Renal Replace-
ment Therapy (RRT) program, from the National Health System
perspective. METHODS: A deterministic Markov chain model,
allowing for incident patients, was designed to predict transitions
between four states (hemodialysis (HD), peritoneal dialysis (PD),
renal transplant (TX), and death (D)) for the period 2007/2016,
providing future incidence, prevalence, and survivability esti-
mates. Transition and mortality probabilities were calibrated
using data from the Spanish Nephrology Society (SEN) and the
Spanish National Statistics Institute (INE) for the period 1996/
2006. Information on direct and indirect costs was gathered from
several sources, including OBLIKUE database, regional ofﬁcial
bulletins, literature review, and expert judgment. Data on utilities
were obtained from a proprietary database (FIS 96/1327
Project). A sensitivity analysis on the main parameters of the
model was performed in order to ensure that results were con-
sistent. RESULTS: For the 2007/2016 period, average patients
per year (HD, PD, and TX) were, respectively: 29,981; 3,348;
26,301. Average costs per patient and year (in 2007 discounted
Euros) were: 39,026; 26,971; and 13,085. Average QALYs per
patient and year were: 0.51; 0.55; and 0.68. Therefore, average
cost-effectiveness was: 75,927; 49,478; and 19,253. TX was the
optimal treatment, regarding cost-effectiveness estimates. Conse-
quently, it was considered as the gold standard. Incremental
Cost-Effectiveness Ratios were: -103,233 (TX vs. HD) and
-156,636 (TX vs. PD). Net Health Proﬁts were: 1.03 (TX vs.
HD) and 0.60 (TX vs. PD). Consistency of these ﬁndings was
supported by the sensitivity analysis. CONCLUSIONS: As
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